Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease
复制标题
DOI：
10.1002/mds.870120618
复制
发表时间：
1997-11-01
影响因子：
8.6
通讯作者：
McCallum, RW
中科院分区：
文献类型：
--
作者：
Soykan, I;Sarosiek, I;McCallum, RW
本研究调查多潘立酮是否可以改善接受左旋多巴治疗的帕金森病患者的胃肠道症状。共研究了11例患者。基线胃排空试验后，患者接受起始剂量多潘立酮20 mg p.o. Q.I.D.在多潘立酮治疗开始后至少4个月重复随访胃排空试验。在开始和每次3个月随访访视时，评价恶心、呕吐、厌食、腹胀、烧心、反流、吞咽困难和便秘症状，并按0-3分量表评分。总体平均随访期为3年。与基线评估相比，患者除吞咽困难和便秘外，所有症状均显著改善（p < 0.05）。同位素标记的固体食物的胃排空明显更快，基线结果为餐后2小时同位素保留60.2 ± 6.4%，而多潘立酮治疗期间为37.0 ± 2.2%（p < 0.05）。患者对帕金森病的总体评估保持稳定或改善。多潘立酮治疗后血清催乳素均升高（P < 0.05）。多潘立酮治疗可显著减轻上消化道症状，加速固体食物的胃排空，但不干扰抗帕金森病治疗的反应。
This study investigated whether domperidone could improve gastrointestinal symptoms in patients with Parkinson's disease who were receiving levodopa therapy. A total of 11 patients were studied. Following a baseline gastric emptying test, patients were treated with a starting dose of domperidone 20 mg p.o. q.i.d. A follow-up gastric emptying test was repeated at least 4 months after starting domperidone therapy. At the beginning and at each 3-month follow-up visit, symptoms of nausea, vomiting, anorexia, abdominal bloating, heartburn, regurgitation, dysphagia, and constipation were evaluated and scored on a scale of 0-3. The overall mean follow-up period was 3 years. Compared with their baseline evaluation, patients experienced a significant improvement in all symptoms (p < 0.05) except dysphagia and constipation. Gastric emptying of an isotope-labeled solid meal was significantly faster, with a baseline result of 60.2 +/- 6.4% retention of isotope 2 h after the meal compared with 37.0 +/- 2.2% retention during domperidone therapy (p < 0.05). Patients' global assessment of Parkinson's disease remained stable or improved. Serum prolactin was elevated in all patients after domperidone therapy (p < 0.05). Domperidone therapy significantly reduces upper gastrointestinal symptoms and accelerates gastric emptying of a solid meal, but does not interfere with response to antiparkinsonism treatment.